Basilea Pharmaceutica Earnings Call Highlights Pipeline Push

Basilea Pharmaceutica ((CH:BSLN)) has held its Q4 earnings call. Read on for the main highlights of the call.

Basilea Pharmaceutica’s latest earnings call painted an upbeat picture of a specialty anti‑infectives player entering a new phase of growth. Management highlighted double‑digit revenue and profit expansion, a much stronger balance sheet, and a robust pipeline funded largely with nondilutive capital, while openly flagging looming patent cliffs and higher R&D as the main medium‑term tests.

Cresemba drives double‑digit growth and market leadership

Cresemba remains the engine of the business, with global in‑market sales rising 27% year-on-year to USD 693 million for the 12 months to September 2025. The drug has moved beyond the launch phase in China and Japan and is now the global market leader by value in its indication, underlining its strategic importance ahead of future generic pressure.

Revenue and profits advance on anti‑infective strength

Total revenue climbed 11.4% to CHF 232.4 million in 2025, driven mainly by Cresemba and Zevtera-related income of CHF 194.4 million. Operating profit reached CHF 51.5 million and net profit CHF 40.2 million, confirming that Basilea has transitioned into a consistently profitable commercial-stage biotech rather than a pure development play.

Royalty income accelerates alongside product demand

Royalty income rose 15.4% year-on-year to CHF 111.6 million, reflecting sustained demand for Cresemba across partnered markets. This recurring, high‑margin revenue stream is becoming an increasingly important pillar of earnings quality as product supply arrangements evolve and partners scale up their own manufacturing.

Cash pile grows and balance sheet de‑risks

Cash, cash equivalents and restricted cash increased 30% to CHF 162.3 million at year-end, while net cash jumped more than threefold to CHF 86.9 million after deducting convertible bonds. Operating cash flow of CHF 62.1 million underlines the business’s improved self-funding capacity and gives management more room to invest ahead of Cresemba’s loss of exclusivity.

Nondilutive funding underwrites major R&D programs

Basilea underscored over USD 430 million in awarded nondilutive R&D funding from agencies such as BARDA and CARB-X, with more than USD 100 million already committed and roughly USD 330 million potentially still available. During the year alone, the company secured USD 70 million of such funding, significantly reducing the need for equity dilution to support late-stage trials.

Convertible debt sharply reduced since 2022

Management has cut convertible debt by CHF 145 million since January 2022, including CHF 21 million in the latest period, leaving CHF 76 million outstanding. This deliberate de‑leveraging, coupled with rising net cash, lowers financial risk and enhances flexibility to pursue business development or buffer future revenue erosion from generics.

Zevtera gains early traction in U.S. launch

Zevtera’s U.S. launch in July 2025 marks a key commercial milestone, with early wins including inclusion on multiple formularies such as Medicaid and 340B, NTAP reimbursement status and a dedicated J-code for outpatient billing. Repeat hospital orders suggest emerging clinical adoption, and Basilea’s partner expects net sales to ramp more meaningfully from the second quarter of 2026.

Pipeline broadens with Phase III‑ready assets

The company expanded and advanced its pipeline by in-licensing ceftibuten-ledaborbactam, a Phase III-ready antibiotic, and pushing antifungal fosmanogepix into a second Phase III trial. Fosmanogepix is now in two global Phase III studies with readouts expected in 2028, while ceftibuten-ledaborbactam should enter Phase III in early 2027 with data anticipated in 2029.

Phase III assets offer sizeable commercial upside

Management sees fosmanogepix generating potential peak sales of about USD 1 billion and ceftibuten-ledaborbactam around USD 500 million if trials succeed. These estimates, while not guaranteed, frame a material mid‑term revenue opportunity that could offset Cresemba’s eventual decline and reshape Basilea’s earnings profile late in the decade.

Real‑world fosmanogepix data strengthens clinical case

Fosmanogepix has already treated more than 430 patients via an expanded access program across 20 countries, providing valuable real‑world evidence. Case experience, including difficult infections such as the 2023 fusarium meningitis outbreak, suggests meaningful clinical benefit and reduced in‑hospital mortality, supporting the drug’s positioning in high‑need, hard‑to‑treat infections.

Guidance signals profitable growth despite higher R&D

For 2026, Basilea guides Cresemba- and Zevtera-related revenue to around CHF 200 million and total revenue growth of roughly 10%, with R&D expenses rising by about 20%. Even so, management expects operating profit to increase by around 20% and cash contribution from the commercial business to grow from CHF 155 million in 2025 to CHF 170 million, implying further operating leverage.

Visible cash generation supports long‑term investment

The company projects approximately CHF 600 million in cumulative cash flow from Cresemba and Zevtera between 2026 and 2030, giving substantial visibility on funding. Combined with large pools of nondilutive funding, this outlook provides significant flexibility to progress Phase III programs and pursue selective business development without overburdening the balance sheet.

R&D spend ramps as pipeline enters late stage

Operating expenses reached CHF 141.5 million in 2025, driven by rising R&D as the portfolio matures. Looking ahead to 2026, R&D is expected to increase by about 20% as Basilea finances two fosmanogepix Phase III trials, prepares ceftibuten-ledaborbactam for Phase III, and initiates a Phase I study with BAL2420, temporarily pressuring margins in exchange for future growth options.

Product mix shifts as partners internalize manufacturing

Management warned that product revenue will decline near term as supply to Pfizer falls while partners transition to their own production capabilities. Although this reduces reported product sales, it should also lower cost of goods sold, altering the revenue mix towards higher-margin royalties and potentially smoothing profitability despite the headline revenue change.

Cresemba patent cliff looms from 2027 onward

Cresemba faces loss of exclusivity with generics anticipated in the U.S. from the fourth quarter of 2027 and in Europe from the second half of 2028, with full-year impact likely visible in 2029. The exact timing and number of generics remain uncertain and outside Basilea’s control, making successful Phase III execution critical to sustain growth later in the decade.

Reliance on partners and milestone timing adds volatility

Commercial performance for assets like Zevtera in the U.S., as well as some regulatory and commercial activities for Cresemba, depends on partners’ execution. In addition, milestone and upfront payments, historically averaging CHF 30–40 million annually, are inherently lumpy, creating modeling noise for investors even if the long‑term value creation path remains intact.

Tax and regulatory factors add further uncertainty

With around CHF 11 million in deferred tax assets left, Basilea expects cash tax outflows to begin around 2027, assuming an indicative tax rate of roughly 11–12%. On the regulatory side, standard late‑stage risks apply: ceftibuten-ledaborbactam’s Phase III design still needs regulatory alignment and may require a second pivotal trial, while enrollment and review dynamics could shift timelines for both lead pipeline assets.

Forward guidance highlights profitable growth and cash strength

Taken together, Basilea’s guidance outlines a company planning to grow revenue and operating profit in 2026, while deliberately front‑loading R&D to prepare its next wave of products. Management’s long‑term view of substantial cumulative cash flow from Cresemba and Zevtera, complemented by large nondilutive funding pools, positions the group to navigate looming generic headwinds if its late‑stage pipeline delivers on expectations.

Basilea’s earnings call showcased a business that is both harvesting strong cash flows from its current portfolio and investing aggressively to secure its post‑Cresemba future. Investors will now watch how quickly Zevtera scales in the U.S. and whether the ambitious Phase III programs stay on track, as these factors will determine whether today’s robust fundamentals translate into durable value beyond the coming patent cliff.